# Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

> **NCT05822752** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 130 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Budigalimab
- **DRUG:** Livmoniplimab
- **DRUG:** Lenvatinib
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT05822752
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-21
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05822752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05822752, "Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05822752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*